NASDAQ$ZVRA
Zevra Therapeutics Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Reported corporate updates and financial results for the third quarter of 2023.
Zevra Therapeutics reported a net revenue of $2.9 million for Q3 2023 and ended the quarter with $83.4 million in cash, cash equivalents, and investments. The company is focused on closing the proposed Acer acquisition, resubmitting the arimoclomol NDA, and completing the Phase 2 trial in idiopathic hypersomnia.
- Arimoclomol NDA resubmission remains on track for end of year filing.
- Proposed acquisition of Acer Therapeutics on track to close in Q4 2023.
- Net revenue of $2.9M was reported for Q3 2023.
- Ended Q3 2023 with $83.4M in cash, cash equivalents, and investments, supporting the forecasted cash runway into 2026.
Headline financials
Revenue & EPS history
Zevra · Revenue · Quarterly
$2.9M
Forward guidance
Zevra is advancing its pipeline programs toward multiple potential value inflection points, focusing on closing the Acer acquisition, resubmitting the arimoclomol NDA, and advancing KP1077 into Phase 3.
Tailwinds
- Arimoclomol NDA resubmission on track for end of year filing.
- Acer Therapeutics acquisition expected to close in Q4 2023, diversifying revenue with OLPRUVA.
- KP1077 Phase 2 trial data expected in the first half of 2024, informing Phase 3 trial design.
- Strong cash balance of $83.4 million supports operating cash runway into 2026.
- Potential commercial launch of arimoclomol in the U.S. if approved.
Headwinds
- R&D expenses increased due to ongoing Phase 2 clinical trial in KP1077 and arimoclomol NDA resubmission.
- G&A expenses increased due to personnel costs and professional fees.
- Net loss for Q3 2023 was ($14.0) million, compared to a net loss of ($6.6) million for the same period in 2022.
- Cash decreased by ($4.0) million compared to June 30, 2023, driven by increased R&D costs and G&A expenses.
- The acquisition of Acer is subject to customary closing conditions, including approval by Acer shareholders.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2023
-0.2%
Avg return
Earnings day
+0.0%
Avg return
5 days after
+3.8%
Avg return
30 days after
45%
20 / 44 earnings
Positive
+35.2%
Q2 2015
Best reaction
-19.4%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +6.0% | +1.6% | -0.1% | |
| Q4 2025 | +21.3% | +9.4% | +6.5% | |
| Q3 2025 | -9.8% | -6.4% | -13.5% | |
| Q1 2025 | +3.0% | +2.7% | +8.3% | |
| Q4 2024 | -2.1% | -2.1% | +10.5% | |
| Q3 2024 | -3.5% | -3.8% | -5.8% | |
| Q2 2024 | +2.6% | +8.2% | +11.5% | |
| Q1 2024 | -2.7% | -5.5% | -10.1% | |
| Q4 2023 | -13.3% | -13.9% | -23.9% | |
| Q3 2023 | -3.5% | -9.0% | +12.7% | |
| Q2 2023 | +3.8% | -4.2% | -2.7% | |
| Q1 2023 | +3.1% | +27.7% | +37.1% | |
| Q4 2022 | -19.4% | -22.8% | +4.9% | |
| Q3 2022 | -18.3% | -17.6% | -19.7% | |
| Q2 2022 | -5.4% | -14.6% | -4.3% | |
| Q1 2022 | +2.0% | +15.9% | +9.5% | |
| Q4 2021 | -4.7% | -1.3% | -15.3% | |
| Q3 2021 | -0.1% | -2.1% | -9.9% | |
| Q2 2021 | -9.4% | -7.2% | -7.6% | |
| Q1 2021 | +3.4% | +10.8% | +65.9% | |
| Q4 2020 | +19.5% | +14.4% | -8.3% | |
| Q3 2020 | -5.2% | +6.2% | +83.0% | |
| Q2 2020 | +8.7% | +46.8% | +48.9% | |
| Q1 2020 | -13.5% | -21.2% | -27.3% | |
| Q4 2019 | -0.9% | -8.5% | -30.9% | |
| Q3 2019 | +11.3% | -5.5% | -21.6% | |
| Q2 2019 | -15.8% | -18.3% | -25.8% | |
| Q1 2019 | +4.9% | +9.0% | +17.2% | |
| Q4 2018 | -14.6% | -16.2% | -32.4% | |
| Q3 2018 | -1.9% | -6.9% | +8.4% | |
| Q2 2018 | +5.5% | +0.0% | +13.7% | |
| Q1 2018 | +16.8% | +23.8% | +35.6% | |
| Q4 2017 | -9.9% | -13.2% | -29.1% | |
| Q3 2017 | +1.4% | +0.0% | +1.4% | |
| Q2 2017 | +8.5% | -8.5% | +9.3% | |
| Q1 2017 | +0.0% | +3.8% | +2.5% | |
| Q4 2016 | +9.7% | +18.1% | +31.9% | |
| Q3 2016 | +3.8% | +3.8% | -3.8% | |
| Q2 2016 | +0.0% | +7.7% | +22.0% | |
| Q1 2016 | -15.7% | — | — | |
| Q4 2015 | +0.7% | — | — | |
| Q3 2015 | -8.8% | — | — | |
| Q2 2015 | +35.2% | — | — | |
| Q1 2015 | -2.7% | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro